Studies on left ventricular hypertrophy regression in arterial hypertension: A clear message for the clinician?

Cesare Cuspidi, Arturo Esposito, Francesca Negri, Carla Sala, Meilikè Masaidi, Valentina Giudici, Alberto Zanchetti, Giuseppe Mancia

Research output: Contribution to journalArticle

Abstract

Background: Evidence-based medicine should provide clear and unbiased information to clinicians. We conducted an analysis on published randomized trials evaluating the effects of antihypertensive therapy on left ventricular (LV) morphology assessed by echocardiography to investigate (i) the consistency of criteria used for definition of LV hypertrophy (LVH) and (ii) the consistency of the way LVH regression and blood pressure (BP) control were reported. Methods: Studies identified by a PubMed search were eligible for inclusion in the analysis, if they fulfilled the following criteria: (i) publication in a peer-reviewed journal within the last 12 years; (ii) double blind, randomized, controlled, parallel-group design; (iii) numerosity of at least 50 adult hypertensive subjects; (iv) follow-up duration of at least 6 months; (v) comparison between single-drugs or association regimens; (vi) LV mass (LVM) or wall thickness measured by echocardiography. Results: Thirty-nine trials, including 9,162 hypertensive subjects of both genders in 78 active treatment arms or in 6 placebo arms were identified. Definition of LVH was provided by 34 studies (87.1%) according to 19 different criteria. All trials evaluated LVH regression as the absolute or relative changes of continuous variables such as LVM index (LVMI) or LV wall thickness. Data concerning prevalence rates of LVM normalization were reported in 12 studies (30.7%). The percentage of patients reaching BP target (

Original languageEnglish
Pages (from-to)458-463
Number of pages6
JournalAmerican Journal of Hypertension
Volume21
Issue number4
DOIs
Publication statusPublished - Apr 2008

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Studies on left ventricular hypertrophy regression in arterial hypertension: A clear message for the clinician?'. Together they form a unique fingerprint.

Cite this